Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Asian J Endosc Surg ; 17(2): e13309, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38584140

RESUMEN

INTRODUCTION: Tokyo Guidelines 2018 (TG18) recommend early laparoscopic cholecystectomy (LC) for low-risk acute cholecystitis (AC); however, some patients undergo delayed LC (DLC) after conservative treatment. DLC, influenced by chronic inflammation, is a difficult procedure. Previous studies on LC difficulty lacked objective measures. Recently, TG18 introduced a novel 25 findings difficulty score, which objectively assesses intraoperative factors. The purpose of this study was to use the difficulty score proposed in TG18 to identify and investigate the predictors of preoperative high-difficulty cases of DLC for AC. METHODS: We retrospectively reviewed 100 patients with DLC after conservative AC treatment. The surgical difficulty of DLC was evaluated using a difficulty score. Based on previous studies, the highest scores in each category were categorized as grades A-C. RESULTS: The severity of AC was mild in 51 patients and moderate in 49. Surgical outcomes revealed a distribution of difficulty scores, with grade C indicating high difficulty, showing significant differences in operative time, blood loss, achieving a critical view of safety, bailout procedures, and postoperative hospital stay compared with grades A and B. Regarding the preoperative risk factors, multivariate analysis identified age >61 years (p = .008), body mass index >27.0 kg/m2 (p = .007), and gallbladder wall thickness >6.2 mm (p = .001) as independent risk factors for grade C in DLC. CONCLUSION: The difficulty score proposed in TG18 provides an objective framework for evaluating surgical difficulty, allowing for more accurate risk assessments and improved preoperative planning in DLC for AC.


Asunto(s)
Colecistectomía Laparoscópica , Colecistitis Aguda , Humanos , Persona de Mediana Edad , Colecistectomía Laparoscópica/efectos adversos , Tokio , Estudios Retrospectivos , Colecistitis Aguda/cirugía , Resultado del Tratamiento
3.
Am Surg ; 89(11): 4764-4771, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-36301856

RESUMEN

BACKGROUND: Patients with pan-peritonitis (PP) due to colorectal perforation have high mortality rate because colorectal perforation causes septic shock. The association between total steroid intake (TSI) and hospital mortality of such patients is not clear. METHODS: One hundred forty-two patients who underwent surgery for PP due to colorectal perforation were reviewed. Patients were divided into two groups by 8000 mg of TSI. The cut-off value of TSI was determined using a receiver operating characteristic curve for hospital mortality. RESULTS: The cut-off value of TSI for hospital mortality was 8000 mg. Patients with TSI>8000 mg had high rate of hemodialysis, hospital mortality, and elevated neutrophil ratio (>95%) compared with those with TSI≤8000 mg. Multivariate analyses revealed that TSI (>8000/≤8000, mg) (OR, 9.669; 95% CI, 1.011-92.49; P = .049) was significantly associated with hospital mortality as well as bleeding volume (>1000/≤1000, mL) (OR, 26.08; 95% CI, 3.566-190.4; P = .001), lymphocyte ratio (≤4/>4, %) (OR, 7.988; 95% CI, 1.498-42.58; P = .015) and C-reactive protein (≤7.5/>7.5, mg/dL) (OR, 41.66; 95% CI, 4.784-33.33; P = .001). DISCUSSION: There was a significant association between TSI and hospital mortality in patients with PP due to colorectal perforation as well as intraoperative bleeding and systemic inflammatory markers.


Asunto(s)
Neoplasias Colorrectales , Peritonitis , Humanos , Mortalidad Hospitalaria , Pronóstico , Estudios Retrospectivos , Esteroides , Peritonitis/etiología
4.
Surg Endosc ; 36(12): 8790-8796, 2022 12.
Artículo en Inglés | MEDLINE | ID: mdl-35556165

RESUMEN

BACKGROUND: Laparoscopic surgery (LS) is reported to reduce postoperative complications and hospital stay compared with open surgery (OP). Because patient selection may have been biased in previous studies, propensity score matching (PSM) analysis was used in this study to test the benefits of LS compared with OP. METHODS: A total of 759 patients with stage I-III colorectal cancer undergoing curative surgery were retrospectively reviewed. To minimize confounding bias between LS and OP groups, a 1:1 PSM analysis was performed based on adjuvant chemotherapy, age, albumin, body mass index, American Society of Anesthesiologists physical status depth of tumor, gender, lymph node dissection, maximum tumor size, obstructive tumor, previous abdominal surgery, pathological stage, tumor differentiation, and tumor location. Statistical analyses including chi-square test, Mann-Whitney U test, univariate analyses and Kaplan-Meier method and log-rank test were performed using the data after PSM to investigate the benefits of LS compared with OP. RESULTS: After PSM analysis, 460 patients remained in the study. The LS group had lower intraoperative blood loss (34 ± 70 vs 237 ± 391, mL; P < 0.001), lower frequency of postoperative small bowel obstruction (SBO) (17/213 vs 30/230; P = 0.045), lower rate of nasogastric tube insertion (7/223 vs 17/213; P = 0.036), and shorter postoperative hospital stay (13 ± 10 vs 25 ± 47, day; P < 0.001) than the OP group. Univariate analyses showed that LS significantly reduced the risk of postoperative SBO (odds ratio [OR] 0.532; 95% confidence interval [CI] 0.285-0.995; P = 0.048) and nasogastric tube insertion (OR 0.393; 95% CI 0.160-0.967; P = 0.042) compared with OP. There were no significant differences in OS and RFS between the groups. CONCLUSIONS: LS reduced intraoperative blood loss, frequency of postoperative SBO, rate of nasogastric tube insertion, and postoperative hospital stay compared with OP.


Asunto(s)
Neoplasias Colorrectales , Obstrucción Intestinal , Laparoscopía , Humanos , Puntaje de Propensión , Tiempo de Internación , Estudios Retrospectivos , Pérdida de Sangre Quirúrgica , Laparoscopía/métodos , Obstrucción Intestinal/epidemiología , Obstrucción Intestinal/etiología , Obstrucción Intestinal/prevención & control , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/prevención & control , Neoplasias Colorrectales/cirugía , Neoplasias Colorrectales/complicaciones , Resultado del Tratamiento
5.
Surg Today ; 52(8): 1160-1169, 2022 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-35015151

RESUMEN

PURPOSE: The pan-immune-inflammation value (PIV) is useful for stratifying outcomes in patients with metastatic colorectal cancer. However, it is unclear whether preoperative PIV can predict the surgical outcomes of patients with stage I-III colorectal cancer who receive surgery. METHODS: The records of 758 patients with stage I-III colorectal cancer who received surgical treatment were retrospectively reviewed. The preoperative PIV was calculated as follows: (neutrophil count × platelet count × monocyte count)/lymphocyte count. The cut-off value was determined using a receiver operating characteristic curve for overall survival. RESULTS: The cut-off value of the preoperative PIV was 376. Five hundred sixty-eight patients (74.9%) had low values (≤ 376), and 190 (25.1%) had high values (> 376). Univariate and multivariate analyses revealed that the PIV (> 376/ ≤ 376) (HR 2.485; 95% CI 1.552-3.981, P < 0.001) was significantly associated with overall survival, as well as age (> 60/ ≤ 60, years) (HR 1.988; 95% CI 1.038-3.807, P = 0.038), globulin-to-albumin ratio (> 0.83/ ≤ 0.83) (HR 2.013; 95% CI 1.231-3.290, P = 0.005) and postoperative complication (C-D grade III-V/0-II) (HR 1.991; 95% CI 1.154-3.438, P = 0.013). The Kaplan-Meier method and log-rank test showed significant differences in overall survival between patients with stage I-III disease with high (> 376) and low (≤ 376) PIVs. CONCLUSION: The preoperative PIV is useful for predicting surgical outcomes in patients with stage I-III colorectal cancer.


Asunto(s)
Neoplasias Colorrectales , Inflamación , Neoplasias Colorrectales/patología , Neoplasias Colorrectales/cirugía , Humanos , Recuento de Linfocitos , Persona de Mediana Edad , Neutrófilos/patología , Pronóstico , Estudios Retrospectivos
6.
Gan To Kagaku Ryoho ; 49(13): 1882-1884, 2022 Dec.
Artículo en Japonés | MEDLINE | ID: mdl-36733031

RESUMEN

We experienced 2 cases of Stage Ⅳ colorectal cancer obtained long-term survival by chemotherapy with only capecitabine. Case 1: Seventy-one-years-old male was performed open sigmoid colectomy, D2 dissection for sigmoid colon cancer. Pathological diagnosis was pT4aN2aM0, pStage Ⅲc. Capecitabine plus oxaliplatin(CAPOX)was performed as adjuvant chemotherapy for 6 months consequently. Two-years after operation, peritoneal dissemination was found, and CAPOX plus bevacizumab(BEV)was started. Due to appearance of renal disfunction and proteinuria, only capecitabine was continued. Since then, 60 months have been passed without disease progression. Case 2: Seventy-six-years-old female was diagnosed as ascending colon cancer with multiple lung metastases. She had initially given systematic chemotherapy with CAPOX plus BEV. Grade 2 adverse effect(numbness and diarrhea)appeared, then the chemotherapy was discontinued. Seven months later, bowel obstruction due to tumor growth was appeared, and open right-hemi colectomy, with D3 dissection was performed for relief of symptoms. Pathological diagnosis was pT3N1bM1a, pStage Ⅳa. With her request, chemotherapy was performed with only capecitabine. Although lung metastasis was slowly progressed, for 72 months she has maintained good general condition since the chemotherapy with only capecitabine was started.


Asunto(s)
Neoplasias del Colon , Neoplasias Colorrectales , Humanos , Masculino , Femenino , Anciano , Capecitabina/efectos adversos , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias del Colon/cirugía , Oxaliplatino/efectos adversos , Bevacizumab/uso terapéutico , Quimioterapia Adyuvante/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Fluorouracilo/efectos adversos
7.
Am Surg ; 87(11): 1802-1808, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-33522253

RESUMEN

OBJECTIVE: To explore the impact of appendectomy history on emergence of Parkinson's disease (PD). BACKGROUND: Although there are several studies to investigate the relationship between appendectomy history and emergence of PD, the results are still controversial. METHODS: We performed a comprehensive electronic search of the literature (the Cochrane Library, PubMed, and the Web of Science) up to April 2020 to identify studies that had employed databases allowing comparison of emergence of PD between patients with and those without appendectomy history. To integrate the impact of appendectomy history on emergence of PD, a meta-analysis was performed using random-effects models to calculate the risk ratio (RR) and 95% confidence interval (CI) for the selected studies, and heterogeneity was analyzed using I2 statistics. RESULTS: Four studies involving a total of 6 080 710 patients were included in this meta-analysis. Among 1 470 613 patients with appendectomy history, 1845 (.13%) had emergences of PD during the observation period, whereas among 4 610 097 patients without appendectomy history, 6743 (.15%) had emergences of PD during the observation period. These results revealed that patients with appendectomy history and without appendectomy had almost the same emergence of PD (RR, 1.02; 95% CI, .87-1.20; P = .83; I2 = 87%). CONCLUSION: This meta-analysis has demonstrated that there was no significant difference in emergence of PD between patients with and those without appendectomy history.


Asunto(s)
Apendicectomía , Enfermedad de Parkinson , Apendicectomía/efectos adversos , Bases de Datos Factuales , Humanos , Oportunidad Relativa , Enfermedad de Parkinson/etiología
8.
Oncologist ; 26(3): 196-207, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33031622

RESUMEN

BACKGROUND: Recent retrospective subgroup analyses of patients with unresectable colon cancer (CC) receiving systemic chemotherapy have demonstrated that there is a significant difference in treatment outcome between patients with right-sided CC (RSCC) and those with left-sided CC (LSCC). However, it is impossible to divide patients with CC randomly into RSCC and LSCC groups before surgery. Therefore, the aim of this study is to explore the impact of primary tumor location (PTL) on survival after curative surgery for patients with CC using propensity score-matching (PSM) studies instead of randomization. MATERIALS AND METHODS: We performed a comprehensive electronic search of the literature up to January 2019 to identify studies that had used databases allowing comparison of postoperative survival between patients with RSCC and those with LSCC. To integrate the impact of PTL on 5-year overall survival (OS) after curative surgery, a meta-analysis was performed using random-effects models to calculate the risk ratio (RR) and 95% confidence interval (CI) for the selected PSM studies. RESULTS: Five studies involving a total of 398,687 patients with CC were included in this meta-analysis. Among 205,641 patients with RSCC, 69,091 (33.6%) died during the observation period, whereas among 193,046 patients with LSCC, 63,380 (32.8%) died during the same period. These results revealed that patients with RSCC and those with LSCC had almost the same 5-year OS (RR, 0.98; 95% CI, 0.89-1.07; p = .64; I2 = 97%). CONCLUSION: This meta-analysis has demonstrated that there was no significant difference in 5-year OS between patients with RSCC and those with LSCC after curative resection. IMPLICATIONS FOR PRACTICE: To integrate the impact of primary tumor location (PTL) on 5-year overall survival (OS) after curative surgery, five propensity score-matching (PSM) studies involving a total of 398,687 patients with colon cancer (CC) were included in this meta-analysis. Among 205,641 patients with right-sided CC (RSCC), 69,091 (33.6%) died during the observation period, whereas among 193,046 patients with left-sided CC (LSCC), 63,380 (32.8%) died during the same period. These results revealed that patients with RSCC and those with LSCC had almost the same 5-year OS (risk ratio, 0.98; 95% confidence interval, 0.89-1.07; p = .64; I2 = 97%).


Asunto(s)
Neoplasias del Colon , Neoplasias del Colon/tratamiento farmacológico , Neoplasias del Colon/cirugía , Humanos , Pronóstico , Puntaje de Propensión , Estudios Retrospectivos , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA